Acinetobacter baumannii is an opportunistic pathogen that poses an increasing threat in the
health-care community. Colistin is one of the promising options for treatment of multidrug …

Background and Aim: Colistin is increasingly being used as a “last-line” therapy to treat
infections caused by multidrug-resistant (MDR) Acinetobacter baumannii isolates, when …

Objectives Colistin resistance rates are rising globally among multidrug-resistant Gram-
negative bacilli, including Acinetobacter baumannii (A. baumannii). A new type of resistance …

Background: Acinetobacter baumannii (AB) is increasingly becoming a clinically relevant
organism due to the rising number of associated nosocomial infections. The therapeutic …

Colistin is one of the most effective alternatives for treating Acinetobacter baumannii
infections. The aim of this study was to determine colistin resistance and heteroresistance …

Purpose Colistin is a drug of last resort for treating multidrug-resistant Acinetobacter
baumannii infections. Unfortunately, colistin-resistant A. baumannii (CoR-AB) has been …

Introduction The development of colistin resistance in Acinetobacter baumannii during
treatment has been identified in certain patients, often leading to prolonged or recurrent …

Objectives: We aimed to describe the mechanisms of colistin resistance in Acinetobacter
baumannii. Materials and Methods: Twenty-nine patients diagnosed with colistin-resistant A …

Background Colistin-resistant/carbapenem-resistant Acinetobacter baumannii is a
significant challenge for antibiotic treatment and infection control policies. Since 2012, in …

Acinetobacter baumannii is an opportunistic pathogen in healthcare facilities responsible for
nosocomial infections mostly in immunocompromised patients. Colistin resistance is …